Lilly to Acquire Ajax Therapeutics to Advance Treatments for Myelofibrosis and Polycythaemia Vera
Tuesday, April 28, 2026
Eli Lilly and Company has entered into a definitive agreement to acquire Ajax Therapeutics.
Ajax’s lead candidate, AJ1-11095, is an investigational, once-daily oral Type II JAK2 inhibitor. It is currently being evaluated in a Phase 1 clinical trial (AJX-101) involving patients with myelofibrosis who have previously received treatment with Type I JAK2 inhibitors.
Existing approved JAK2 inhibitors target the Type I conformation of JAK2. While these therapies provide symptom relief, many patients discontinue treatment due to limited durability or loss of response. AJ1-11095 has been designed to selectively target the Type II conformation of JAK2, with the aim of improving treatment durability and offering an alternative for patients who develop resistance to current therapies. The Phase 1 trial began in late 2024, and dose selection for further clinical development is expected in 2026.
The acquisition builds on Lilly’s prior involvement as a strategic investor in Ajax. The company plans to advance AJ1-11095 through clinical development, with the goal of progressing to later-stage trials following proof-of-concept data anticipated in 2026.
Ajax was established to develop more selective and potent JAK2 inhibitors based on research from its scientific founders. The company has since progressed its lead programme into early-stage clinical development and aims to address unmet needs in MPN treatment.
Under the terms of the agreement, Ajax shareholders may receive up to $2.3 billion in cash, including an upfront payment and additional payments linked to clinical and regulatory milestones.
The transaction remains subject to customary closing conditions, including regulatory approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Following completion, the acquisition will be reflected in Lilly’s financial results in accordance with generally accepted accounting principles.
Source: lilly.com
